1982
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
Elsworth J, Sandler M, Lees A, Ward C, Stern G. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. Journal Of Neural Transmission 1982, 54: 105-110. PMID: 6809891, DOI: 10.1007/bf01249283.Peer-Reviewed Original Research
1980
The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man
Thornton C, Doré C, Elsworth J, Herbert M, Stern G. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology 1980, 70: 163-166. PMID: 6776576, DOI: 10.1007/bf00435308.Peer-Reviewed Original ResearchConceptsMonoamine oxidase B inhibitorsSelective monoamine oxidase B inhibitorHealthy young male adultsEffect of deprenylSystolic blood pressureB inhibitorBalanced cross-over designStage 2 sleepPlatelet MAO activityYoung male adultsCross-over designPhenylethylamine excretionBlood pressureDrug withdrawalSleep disturbancesMovement sleepLevel of alertnessMAO activityMAO inhibitorsSleepMale adultsDrugsSignificant increaseDeprenylPhenylethylamine concentrationsTele-methylhistamine is a specific MAO B substrate in man
Elsworth J, Glover V, Sandler M. Tele-methylhistamine is a specific MAO B substrate in man. Psychopharmacology 1980, 69: 287-290. PMID: 6774369, DOI: 10.1007/bf00433097.Peer-Reviewed Original ResearchDopamine Oxidation and Its Inhibition by (—)-Deprenyl in Man
Glover V, Elsworth J, Sandler M. Dopamine Oxidation and Its Inhibition by (—)-Deprenyl in Man. Journal Of Neural Transmission. Supplementa 1980, 163-172. PMID: 6776235, DOI: 10.1007/978-3-7091-8582-7_18.Peer-Reviewed Original Research
1979
DOPAMINE OXIDATION AND ITS INHIBITION BY (−)-DEPRENYL IN HUMAN BRAIN AND TISSUES
Glover V, Elsworth J, Sandler M. DOPAMINE OXIDATION AND ITS INHIBITION BY (−)-DEPRENYL IN HUMAN BRAIN AND TISSUES. 1979, 201-203. DOI: 10.1016/b978-1-4832-8363-0.50063-x.Peer-Reviewed Original ResearchSELECTIVE MAO INHIBITION: A NEW STRATEGY IN THE TREATMENT OF PARKINSON'S DISEASE
Elsworth J, Glover V, Sandler M. SELECTIVE MAO INHIBITION: A NEW STRATEGY IN THE TREATMENT OF PARKINSON'S DISEASE. 1979, 1575-1577. DOI: 10.1016/b978-1-4832-8363-0.50482-1.Peer-Reviewed Original Research
1978
Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’
Elsworth J, Glover V, Reynolds G, Sandler M, Lees A, Phuapradit P, Shaw K, Stern G, Kumar P. Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’. Psychopharmacology 1978, 57: 33-38. PMID: 96466, DOI: 10.1007/bf00426954.Peer-Reviewed Original ResearchConceptsMonoamine oxidase B inhibitorsSelective monoamine oxidase B inhibitorNormal dietCheese effectB inhibitorHuman intestinal mucosaNormal human intestinal mucosaPressor responseOral tyraminePressor reactionDeprenyl administrationAdverse reactionsMonoamine oxidase AIntestinal mucosaOxidase AHuman plateletsPlatelet enzymeDeprenylComplete inhibitionVolunteersDietTyramineInhibitorsMucosaAdministration
1977
DEPRENYL IN PARKINSON'S DISEASE
Lees A, Kohout L, Shaw K, Stern G, Elsworth J, Sandler M, Youdim M. DEPRENYL IN PARKINSON'S DISEASE. The Lancet 1977, 310: 791-795. PMID: 71602, DOI: 10.1016/s0140-6736(77)90725-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDouble-blind crossover trialDoses of levodopaEarly morning akinesiaPeripheral decarboxylase inhibitorLevodopa-induced dyskinesiaTotal daily dosesMajority of patientsIdiopathic Parkinson's diseaseDose akinesiaUntreated patientsCrossover trialDosage reductionDaily dosesDecarboxylase inhibitorTherapeutic effectCheese effectLarge dosesPatientsLevodopaAlternate daysAkinesiaDeprenylDiseaseB inhibitor